ILet B1 Tablet PR contains a combination of Glimepiride 1mg and Metformin 500mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The extended-release formulation of ILet B1 Tablet PR ensures a gradual release of active ingredients, promoting sustained blood glucose control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. This combination therapy is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve optimal glycemic targets. ILet B1 Tablet PR should be administered once daily with meals to minimize gastrointestinal discomfort. Regular monitoring of blood glucose levels, renal function, and potential adverse effects such as hypoglycemia and lactic acidosis is essential during treatment. Contraindications include severe renal impairment, diabetic ketoacidosis, and hypersensitivity to components. This combination offers a complementary mechanism of action to improve glycemic control in type 2 diabetes, supporting better long-term outcomes when used as part of a comprehensive diabetes management plan.